WO2006001380A1 - 物質の製造法 - Google Patents
物質の製造法 Download PDFInfo
- Publication number
- WO2006001380A1 WO2006001380A1 PCT/JP2005/011637 JP2005011637W WO2006001380A1 WO 2006001380 A1 WO2006001380 A1 WO 2006001380A1 JP 2005011637 W JP2005011637 W JP 2005011637W WO 2006001380 A1 WO2006001380 A1 WO 2006001380A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- gene
- glutamine
- microorganism
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/14—Glutamic acid; Glutamine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
- C12P13/227—Tryptophan
Definitions
- the present invention relates to a microorganism belonging to the genus Escherichia having the ability to generate and accumulate a substance synthesized using nitrogen supplied from L-gnoretamine or L_glutamine, and L using the microorganism. —Gnoretamine or a method for producing the substance.
- L-gnoretamine itself is a substrate for protein synthesis, and in the biosynthesis of purine and pyrimidine nucleic acids and amino acids such as L-arginine, L-histidine, L-tryptophan, and L-asparagin. Nitrogen supply substrate.
- GS glutamine synthetase
- GlnE protein glutamine synthetase zeadenylyltransferase
- GlnB protein PII regulatory protein for glutamine synthetase 0 or less
- the GlnB protein When the GlnB protein is uridylylated, the GlnE protein promotes GS deadenylation, and conversely, the GlnB protein is uridylated, and in other cases, the GS adenylylation by the GlnE protein. Promote.
- the GlnB protein uridilyl and uridilyl are determined by the protein encoded by the glnD gene. Since L-glutamine promotes deuridylation, GS is adeurilylated, reducing its activity, and regulating L-glutamine synthesis.
- 2-year-old xognoretaric acid promotes uridylation of GlnB protein, and thus L-glutamine synthesis is promoted by the reverse scheme (Non-patent Documents 1 and 2).
- Patent Document 1 describes that Escherichia coli that produces and accumulates L_glutamine by modifying the GS adenylation site so that it is not adenylylated and enhancing gene expression has been obtained. The production is only 1.3g / L.
- glutamine-producing bacteria Corynedal Tamcumum flavum, which lacks the glnE gene (Patent Document 2), Corynedal Tamcumum flavum (Patent Document 2), which has a modified g!
- E. coli and E. coli with enhanced expression of E gene and £ ⁇ gene Patent Document 6
- Known force GlnE protein and GlnB protein have reduced or lost activity
- L glutamine or L glutamine Known is a microorganism belonging to the genus Escherichia that has the ability to generate and accumulate a substance that is biosynthesized using nitrogen supplied from the plant, and a method for producing the substance using this microorganism. Tele, nare.
- Non-Patent Document 2 FEMS Microb. Lett., 201, 91-98 (2001)
- Patent Document 1 Japanese Patent Laid-Open No. 2003-164297
- Patent Document 2 JP 2002-300887
- Patent Document 3 JP-A 57-5693
- Patent Document 4 US Pat. No. 5,939,295
- Patent Document 5 JP-A-2001-86998
- Patent Document 6 Japanese Patent Laid-Open No. 2002-355087
- An object of the present invention is to provide a microorganism belonging to the genus Escherichia having the ability to generate and accumulate a substance biosynthesized using nitrogen supplied from L-glutamine or L-gnoretamine, and the microorganism Means for solving the problem of providing L-gnoretamine or a method for producing the substance
- the present invention relates to the following (1) to (: 10).
- GlnE protein glutamine synthetase adenylyltransferase
- GlnB protein glutamine synthetase regulatory protein ⁇
- amino acid is an amino acid selected from the group consisting of L arginine, L tryptophan, L histidine, and L glutamic acid.
- Nucleic acid is adenosine, inosine, guanosine, xanthosine, cytidine, uridine, thymidine, 5'-adenylic acid, 5'-inosinic acid, 5'-guanylic acid, 5, -cytidylic acid, 5 'xanthylic acid, 5'
- the microorganism according to any one of the above (1) to (3) is cultured in a medium, and a substance biosynthesized using nitrogen supplied from L dartamine or L-gnoretamine is produced in the medium. Accumulating and collecting L-glutamine or the substance from the medium Rutamine or a method for producing the substance.
- amino acid is an amino acid selected from the group consisting of L-arginine, L-tryptophan, L-histidine, and L-glutamic acid.
- Nucleic acid is adenosine, inosine, guanosine, xanthosine, cytidine, uridine, thymidine, 5'-adenylic acid, 5'-inosinic acid, 5'-guanylic acid, 5'-cytidylic acid, 5'-xanthylic acid, The production method of (8) above, which is a nucleic acid selected from the group consisting of 5'-uridylic acid and 5'-thymidylic acid.
- a microorganism belonging to the genus Escherichia having the ability to generate and accumulate a substance that is biosynthesized using nitrogen supplied from L_glutamine or L-gnoretamine, and the microorganism L-gnoretamine or a method for producing the material is provided.
- Microorganisms belonging to the genus Escherichia with reduced or lost activity of GlnE protein and GlnB protein are introduced with the glffE gene or glnE gene deletion mutation of existing microorganisms belonging to the genus Escherichia [JHMiller, Experiments in Molecular Genetics, Col d Spring Harbor Lab. (1972)], a method of accumulating in one microorganism belonging to the genus Escherichia, and selecting a strain whose GlnE protein or GlnB protein activity has decreased or lost after mutation treatment such as UV irradiation Method or chromosome D of microorganisms belonging to the genus Escherichia
- the glnE gene and the glnB gene each comprise a sequence obtained by adding a base sequence including a region that regulates the expression of the gene such as a promoter sequence to the base sequence encoding the GlnE protein or GlnB protein.
- the microorganism belonging to the microorganism is a microorganism in which the activity of the GlnE protein and the GlnB protein is reduced by introducing the mutation described above, compared to the strain (parent strain) before the mutation introduction, preferably 80% or less, preferably Refers to a microorganism that has been reduced to 50% or less, more preferably 30% or less, even more preferably 20%, particularly preferably 10% or less, and most preferably 5% or less.
- the activity of GlnE protein and GlnB protein can be measured by a known method.
- Examples of a method for introducing a deletion, substitution or addition of a base into a chromosomal DNA gene of a microorganism include a method using homologous recombination.
- a method using homologous recombination a mutant gene into which a base deletion, substitution or addition has been introduced is introduced into which a base deletion or the like is introduced, or a gene which cannot replicate autonomously in a host cell.
- a method using a plasmid for homologous recombination that can be prepared by ligation with a plasmid DNA having a drug resistance gene can be mentioned, and a preferred method using homologous recombination is using a homologous recombination system of lambda phage. And a method of introducing a base deletion, substitution or addition [Proc. Natl. Acad. Sci. USA, 97, 6641-6645 (2000)].
- a transformant in which the plasmid for homologous recombination is incorporated into chromosomal DNA by homologous recombination using drug resistance as an indicator select.
- the obtained transformed strain is cultured in a medium not containing the drug for several hours to 1 day, and then applied to the drug-containing agar medium and the drug-free agar medium, and the latter is not grown on the former medium.
- a strain that can grow in the medium a strain that has undergone the second homologous recombination on chromosome DNA can be obtained.
- a linear DNA containing a gene to which a base deletion, substitution or addition is to be introduced is incorporated into a cell, and homologous recombination is performed between the chromosomal DNA and the introduced linear DNA. It is a way to wake up.
- This method comprises a microorganism belonging to the genus Escherichia having the ability to take up linear DNA, preferably Escherichia coli, more preferably a phage-derived set.
- Recombinant protein group (Red recombination system) can be expressed and used for rusieria
- Escherichia coli expressing ⁇ Red recombination system has pKD46 [available from Escherichia coligenetic stock center (Yale University, USA)] which is a plasmid DNA containing Red recombination system gene. You can raise S. E. coli JM101 strain.
- any drug resistance gene can be used as long as it is a drug resistance gene that imparts drug resistance to a drug to which a host microorganism is sensitive.
- examples of drug resistance genes include kanamycin resistance gene, chloramphenicol resistance gene, gentamicin resistance gene, spectinomycin resistance gene, tetracycline resistance gene and ampicillin resistance gene. Etc.
- a gene that can be used for negative selection refers to the gene in a host microorganism. When expressed, it refers to a gene that is lethal to the microorganism under certain culture conditions. Examples of the gene include a ⁇ gene derived from a microorganism belonging to the genus Bacillus [
- DNA having homology with DNA existing outside both ends of the region on the chromosomal DNA to which substitution or deletion is to be introduced, present at both ends of the above linear DNA is linear DNA. It is arranged in the same direction as that on the chromosomal DNA, and the length is preferably about 10 to 100 bp, more preferably about 20 to 50 bp, and further preferably about 30 to 40 bp.
- the nucleotide sequence recognized by the yeast-derived Flp recombinase is not particularly limited as long as it is recognized by the protein and catalyzes homologous recombination, but is preferably a DNA having the nucleotide sequence represented by SEQ ID NO: 9.
- the DNA having the homology is a DNA having the homology that the homologous recombination occurs in the target region on the chromosomal DNA.
- Examples thereof include DNA having a homology of 80% or more, preferably 90% or more, more preferably 95% or more, and still more preferably 100%.
- the linear DNA fragment can be prepared by PCR.
- the desired linear DNA can be obtained by restriction enzyme treatment. More specific methods for introducing base deletion, substitution or addition into the chromosomal DNA of a microorganism using homologous recombination include the following methods 1 to 4.
- Method 1 Introduce the linear DNA (a) or (d) above into the host microorganism, and select a transformant in which the linear DNA is inserted into the chromosomal DNA by homologous recombination using drug resistance as an index. Method.
- Method 2 By introducing the linear DNA of (b) above into the transformed strain obtained by Method 1 above and deleting the drug gene inserted into the chromosomal DNA by the method, A method of substituting or deleting a region of.
- the linear DNA of (c) above is introduced into a host microorganism, and a transformant in which the linear DNA is inserted into chromosomal DNA by homologous recombination is selected using drug resistance as an index.
- DNA that has homology to DNA located outside both ends of the target region for substitution or deletion on the chromosomal DNA is synthesized by ligating DNA in the same direction as that on the chromosomal DNA. Introduce into the transformant obtained in 1],
- the linear DNA of (d) above is introduced into a host microorganism, and a transformant in which the linear DNA is inserted into chromosomal DNA by homologous recombination is selected using drug resistance as an index.
- any method can be used as long as it introduces DNA into the microorganism, for example, a method using calcium ion [Proc. Natl. Acad. Sci "USA, 69, 2110 (1972)], protoplast method (Japanese Patent Laid-Open No. 63-248394), electoral position method [Nucleic Acids Res., 16. 6127 (1988)] Etc.
- a drug is obtained by using a linear DNA in which an arbitrary gene to be inserted on a chromosomal DNA is inserted near the center of the DNA. At the same time that the resistance gene is deleted, any gene can be inserted into the chromosomal DNA.
- the above methods 2 to 4 are methods that do not leave a foreign gene such as a drug resistance gene and a gene that can be used for negative selection on the chromosomal DNA of the finally obtained transformant. Therefore, by repeating the operation of the method using the same drug resistance gene and a gene that can be used for negative selection, it is easy to delete bases in two or more regions at different positions on the chromosomal DNA. Microorganisms having substitutions or additions can be produced.
- Microbial power with decreased or lost activity of GlnE protein and GlnB protein obtained by the above method ability to generate and accumulate substances biosynthesized using nitrogen supplied from L-gnoretamine or L-glutamine
- the presence of the microorganism can be easily confirmed by culturing the microorganism in a medium, and producing or accumulating L-glutamine or the substance in the medium by a known method, for example, analysis using HPLC or bioassay.
- Microorganisms belonging to the genus Escherichia that lose the activity of GlnE protein and GlnB protein that can be prepared by the above method and produce and accumulate glutamine include Escherichia coli lacking the glnE gene and the GlnB gene. 'Kori JGLBE1 can be raised.
- Microorganisms belonging to the genus Escherichia in which the activity of the GlnE protein and GlnB protein is reduced or lost are biosynthesized using nitrogen supplied by L-glutamine, which not only has the ability to produce and accumulate L-gnoretamine. It also has the ability to generate and accumulate materials.
- Examples of biosynthesized substances using nitrogen supplied from L_glutamine include amino acids and nucleic acids.
- amino acids L-arginine, L-histidine, L- Nucleic acids such as tryptophan and L-gnoretamic acid are preferably adenosine, inosine, guanosine, xanthosine, cytidine, uridine, thymidine, 5'_dururic acid, 5 'inosinic acid, 5'-guanylic acid, 5'-cytidylic acid 5'-xanthylic acid 5'-uridylic acid and 5'-thymidylic acid.
- Microorganisms belonging to the genus Escherichia that have the ability to produce and accumulate substances that are biosynthesized using nitrogen supplied from L-glutamine, with the activity of GlnE and GlnB proteins decreased or lost.
- Escherichia coli JGLBE1 as well as microorganisms obtained by the above method,
- a microorganism obtained by using a method such as a method of selecting a cell line having a higher resistance to an analog of the substance than a wild type strain alone or in combination can be mentioned.
- L_glutamine power A known microorganism belonging to the genus Escherichia having the ability to produce a biosynthetic substance using supplied nitrogen is L-arginine-producing bacterium Escherichia coli (Japanese Patent Laid-Open No. 57-5693). Etc.), such as L-tryptophan producing bacterium Escherichia coli (US Pat. No.
- L histidine producing bacterium Escherichia coli JP 2001-86998
- L glutamic acid producing bacterium Escherichia coli specialty
- 5'-inosinic acid producing bacteria such as Escherichia coli (JP 2002-355087), 5'-guanylic acid producing bacteria Escherichia coli (JP 2002-355087), etc.
- a microorganism belonging to the genus Escherichia that can be prepared by the above method 1 is cultured in a medium, and L-glutamine or a substance that is biosynthesized using nitrogen supplied from L-glutamine is generated and accumulated in the medium.
- L-glutamine or the substance can be produced by collecting L-gnoretamine or the substance from the medium.
- Examples of the substance biosynthesized using nitrogen supplied from L-glutamine include the substance 1 described above.
- the medium used in the production method of the present invention uses the growth of microorganisms of the present invention such as carbon source, nitrogen source, inorganic salts, vitamins, and nitrogen supplied from L-glutamine or L-gnoretamine. As long as the nutrients necessary for biosynthesis of the biosynthesized substance are included, the synthetic medium and the natural medium can be misaligned.
- any carbon source that can be assimilated by the microorganism to be used can be used.
- Sugar such as fructose, alcohols such as ethanol and glycerol, organic acids such as acetic acid, etc. Can give.
- nitrogen source examples include ammonia, ammonium salts such as ammonium sulfate, nitrogen compounds such as amamine, natural nitrogen sources such as peptone and soybean hydrolysate.
- inorganic salts include potassium phosphate, magnesium sulfate, sodium chloride salt, ferrous sulfate, Examples include potassium carbonate.
- vitamins examples include piotin and thiamine.
- a substance required for growth by the microorganism of the present invention for example, a required amino acid in the case of an amino acid-requiring microorganism
- a required amino acid in the case of an amino acid-requiring microorganism
- the culture is preferably performed under aerobic conditions such as shaking culture and aeration-agitation culture.
- the culture temperature is 20-50 ° C, preferably 20-42 ° C, more preferably 28-38 ° C.
- the culture pH is 5-9, preferably 6-7.5.
- the culture time is 5 hours to 5 days, preferably 16 hours to 3 days.
- Substances biosynthesized using nitrogen supplied from L-gnoretamine or L-glutamine accumulated in the medium can be collected by ordinary purification methods.
- L-gnoretamine can be collected by culturing and removing solids from the cells by centrifugation or the like, followed by ion exchange, concentration, and crystal fractionation.
- the plasmids pKD46, pKD3, and pCP20 shown below are obtained by obtaining a Escherichia coli strain carrying the plasmid from the Escherichia coli Collogenetic Stock Center (Yale University, USA) and extracting it from the strain by a known method. It was.
- Escherichia The base sequences of the gln £ and glnn genes of the K12 strain have already been clarified [Science, 5331. 1453-1474 (1997)] 0 Based on the reported base sequences' Using a Biosystems 8905 DNA synthesizer, the DNA consisting of the nucleotide sequence represented by SEQ ID NOs: 1 and 2 as the primer DNA for gene deletion, the SEQ ID NOs: 3 and 4 as the primer DNA for the glnE gene deletion DNA comprising the nucleotide sequence represented was synthesized. Synthesized primer DNA is above the target gene for each deletion. The design was based on the base sequence consisting of 36 bp located downstream and downstream.
- PCR was performed using the above synthetic DNA as a primer set and pKD3DNA as a saddle type.
- PCR is 10 ng of plasmid DNA, each primer is 0.5 ⁇ mol / L, EfiiDNA polymerase (Stratagene) 2.5 units, Pfu DNA polymerase X 10 buffer (Stratagene) 4 ⁇ L, deoxyNTP 200 ⁇ mol each 40 ⁇ L of the reaction solution containing / L was used, and the process consisting of 94 ° C for 1 minute, 55 ° C for 2 minutes, and 72 ° C for 3 minutes was repeated 30 times.
- the resulting upper layer was mixed with 2 volumes of cold ethanol and allowed to stand at ⁇ 80 ° C. for 30 minutes. After centrifuging the solution to precipitate DNA,
- Escherichia coli JM101 strain lacking £ lnE gene on chromosomal DNA After transformation of Escherichia coli JM101 strain with pKD46, maintain pKD46 on LB agar medium containing 100 mg / l ampicillin Escherichia coli JM101 strain (hereinafter referred to as Escherichia coli JM101 / pKD46) was selected.
- the obtained chloramphenicol resistant strain was replicated on an LB agar medium containing 25 mg / L chloramphenicol, and single colony separation was carried out in a state kept at 42 ° C. Each obtained colony was replicated on an LB agar medium containing 25 mg / L chloramphenicol and an LB agar medium containing 100 mg / L ampicillin, and colonies showing chloramphenicol resistance and ampicillin sensitivity were selected.
- this pKD46-eliminated strain was transformed with pCP20, applied to an LB agar medium containing 100 mg / L ampicillin, and cultured at 30 ° C.
- the grown ampicillin-resistant strain was replicated on a LB agar medium with no drug added, and single colonies were isolated while being kept at 42 ° C. Each colony obtained was replicated on LB agar medium containing no drug, LB agar medium containing 25 mg / L chloramphenicol, and LB agar medium containing 100 mg / L ampicillin, and chloramphenicol sensitive and ampicillin sensitive The colonies showing were selected. Chromosomal DNA was prepared from each of the strains obtained here by a conventional method (Biotechnical Experiments, Japan Biotechnology Society, pages 97-98, Baifukan, 1992). Colony PCR was performed using a primer DNA consisting of the nucleotide sequences represented by SEQ ID NOs: 5 and 6 designed based on the internal sequence of the gkiE gene.
- Colony PCR is performed by touching the colony with a 200 ⁇ 1 pipette tip, 0.5 ⁇ mol / L of each primer, E £ iDNA polymerase 2.5 units, Pfo DNA polymerase X 10 buffer 4 ⁇ m
- the strain that did not show gene amplification was confirmed to be a glnE gene-deficient strain and named Escherichia coli JGLE1.
- Escherichia coli JM101 / pKD46 was transformed with the chloramphenicol resistance gene fragment for glnE gene deletion, and Escherichia coli lacking the ginn gene was obtained. ⁇ Named Kori JGLB 1.
- Escherichia coli JGLE1 After transforming the Escherichia coli JGLE1 strain obtained in (2) above with pKD46, the strain is applied to an LB agar medium containing 100 mg / L ampicillin and cultured at 30 ° C to preserve pKD46. Acquired 'Kori JGLE1 strain (hereinafter referred to as Escherichia coli JGLEl / pKD46). Using the same procedure as in (2) above, Escherichia coli JGLE1 / DKD46 was transformed using the chloramphenicol resistance gene fragment for glnB gene deletion by the electroless method, and the gene on the chromosomal DNA was deleted. A strain recombined was obtained.
- Colony PCR was performed under the conditions of (2) above using a primer DNA consisting of the nucleotide sequence represented by SEQ ID NOs: 7 and 8, designed based on the internal sequence of the £ klS gene. Confirm that the strain in which gene amplification was not observed by the PCR was a glnE gene-deficient strain. It was named Sielihia'coli JGLBE1.
- Escherichia coli JM101, Escherichia coli JGLB1, Escherichia coli JGLE1 and Escherichia coli JGLBE1 obtained in Example 1 were each added to 8 ml of LB medium (lOg / 1 bactotryptone (Difco), 5 g / l yeast extract ( Inoculated into a test tube containing 5 g / l sodium chloride], and cultured at 28 ° C for 17 hours.
- LB medium lOg / 1 bactotryptone (Difco)
- 5 g / l yeast extract Inoculated into a test tube containing 5 g / l sodium chloride
- Each of these cultures was used as a production medium [16 g / L dipotassium hydrogen phosphate, 14 g / L potassium dihydrogen phosphate, 5 g / L ammonium sulfate, 1 g / L citrate (anhydrous), 5 g / L casamino acid (Difco). 10g / L glucose, 10mg / L vitamin B, 25mg / L magnesium sulfate heptahydrate, 50mg / L ferrous sulfate heptahydrate, pH7.2
- the Escherichia coli JGLBE1 obtained in Example 1 was inoculated into a 300 ml Erlenmeyer flask containing 50 ml of LB medium and cultured at 28 ° C. for 17 hours.
- Nesym 7 hydrate, 0.2 g / L iron sulfate 7 hydrate, adjusted with 10 mol / L sodium hydroxide to ⁇ 7.2, glucose, vitamin B, magnesium sulfate 7 hydrate, iron sulfate 7 Hydrate is separate
- 1% was inoculated into a 2L jar mentor containing “added after cooking.”
- Culture medium pH during culture was maintained at pH 7.0 with 18% ammonium hydroxide, culture temperature was 30 ° C, stirring speed was 900 ⁇ m, and culture was performed while aerated with sterile air through a sterile filter. .
- a sterilized 60% gno-lecose solution was fed at a rate of 10 to 13 ml per hour.
- a substance that is biosynthesized using nitrogen supplied from L-glutamine or L-gnoretamine can be efficiently produced.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Steroid Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006528631A JP4898441B2 (ja) | 2004-06-25 | 2005-06-24 | 物質の製造法 |
AT05765117T ATE455845T1 (de) | 2004-06-25 | 2005-06-24 | Verfahren zur herstellung von substanzen |
EP05765117A EP1783203B1 (en) | 2004-06-25 | 2005-06-24 | Process for producing substances |
CN2005800205138A CN101065477B (zh) | 2004-06-25 | 2005-06-24 | 物质的制备方法 |
DE602005019063T DE602005019063D1 (de) | 2004-06-25 | 2005-06-24 | Verfahren zur herstellung von substanzen |
US11/630,396 US8211688B2 (en) | 2004-06-25 | 2005-06-24 | Process for producing L-glutamine using Escherichia coli with deficient glnB and glnE function |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004189012 | 2004-06-25 | ||
JP2004-189012 | 2004-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006001380A1 true WO2006001380A1 (ja) | 2006-01-05 |
Family
ID=35781825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/011637 WO2006001380A1 (ja) | 2004-06-25 | 2005-06-24 | 物質の製造法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8211688B2 (ja) |
EP (1) | EP1783203B1 (ja) |
JP (1) | JP4898441B2 (ja) |
CN (1) | CN101065477B (ja) |
AT (1) | ATE455845T1 (ja) |
DE (1) | DE602005019063D1 (ja) |
ES (1) | ES2337379T3 (ja) |
WO (1) | WO2006001380A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012108493A1 (ja) | 2011-02-09 | 2012-08-16 | 協和発酵バイオ株式会社 | 発酵法による目的物質の製造法 |
WO2013154182A1 (ja) | 2012-04-13 | 2013-10-17 | 協和発酵バイオ株式会社 | アミノ酸の製造法 |
JP7415041B2 (ja) | 2020-03-30 | 2024-01-16 | デサン・コーポレイション | グルタミン生産能を向上させる形質転換用組換えベクターおよびこれを導入した菌株 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010090330A1 (ja) | 2009-02-09 | 2010-08-12 | 協和発酵バイオ株式会社 | L-アミノ酸の製造法 |
CN105695375A (zh) * | 2016-04-25 | 2016-06-22 | 四川农业大学 | 鸭疫里默氏杆菌新型培养基及其制备方法 |
KR102283626B1 (ko) * | 2019-10-31 | 2021-08-02 | 대상 주식회사 | glsB 유전자 불활성화에 의해 아미노산 생산능력이 향상된 균주 및 이의 제조방법 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS575693A (en) | 1980-06-13 | 1982-01-12 | Ajinomoto Co Inc | Production of l-arginine through fermentation process |
JPH05244970A (ja) | 1991-08-07 | 1993-09-24 | Ajinomoto Co Inc | 発酵法によるl−グルタミン酸の製造法 |
US5939295A (en) | 1996-03-29 | 1999-08-17 | Archer Daniels Midland Company | Production of tryptophan by microorganisms |
JP2001086998A (ja) | 1999-09-20 | 2001-04-03 | Kyowa Hakko Kogyo Co Ltd | 発酵法によるアミノ酸の製造法 |
JP2002300887A (ja) * | 2001-02-05 | 2002-10-15 | Ajinomoto Co Inc | 発酵法によるl−グルタミンの製造法及びl−グルタミン生産菌 |
JP2002355087A (ja) | 2000-07-05 | 2002-12-10 | Ajinomoto Co Inc | 発酵法によるヌクレオチドの製造法 |
JP2003164297A (ja) * | 2001-11-30 | 2003-06-10 | Ajinomoto Co Inc | 新規変異型グルタミンシンテターゼ、およびアミノ酸の生産方法 |
JP2004283167A (ja) * | 2003-03-03 | 2004-10-14 | Ajinomoto Co Inc | 発酵法によるl−アルギニン又はl−リジンの製造法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050014236A1 (en) * | 2003-03-03 | 2005-01-20 | Yumi Matsuzaki | Method for producing L-arginine or L-lysine by fermentation |
ES2347875T3 (es) * | 2004-06-25 | 2010-11-22 | Kyowa Hakko Bio Co., Ltd. | Procedimiento para la produccion de dipeptidos. |
-
2005
- 2005-06-24 AT AT05765117T patent/ATE455845T1/de not_active IP Right Cessation
- 2005-06-24 US US11/630,396 patent/US8211688B2/en active Active
- 2005-06-24 WO PCT/JP2005/011637 patent/WO2006001380A1/ja active Application Filing
- 2005-06-24 CN CN2005800205138A patent/CN101065477B/zh active Active
- 2005-06-24 ES ES05765117T patent/ES2337379T3/es active Active
- 2005-06-24 JP JP2006528631A patent/JP4898441B2/ja active Active
- 2005-06-24 EP EP05765117A patent/EP1783203B1/en active Active
- 2005-06-24 DE DE602005019063T patent/DE602005019063D1/de active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS575693A (en) | 1980-06-13 | 1982-01-12 | Ajinomoto Co Inc | Production of l-arginine through fermentation process |
JPH05244970A (ja) | 1991-08-07 | 1993-09-24 | Ajinomoto Co Inc | 発酵法によるl−グルタミン酸の製造法 |
US5939295A (en) | 1996-03-29 | 1999-08-17 | Archer Daniels Midland Company | Production of tryptophan by microorganisms |
JP2001086998A (ja) | 1999-09-20 | 2001-04-03 | Kyowa Hakko Kogyo Co Ltd | 発酵法によるアミノ酸の製造法 |
JP2002355087A (ja) | 2000-07-05 | 2002-12-10 | Ajinomoto Co Inc | 発酵法によるヌクレオチドの製造法 |
JP2002300887A (ja) * | 2001-02-05 | 2002-10-15 | Ajinomoto Co Inc | 発酵法によるl−グルタミンの製造法及びl−グルタミン生産菌 |
JP2003164297A (ja) * | 2001-11-30 | 2003-06-10 | Ajinomoto Co Inc | 新規変異型グルタミンシンテターゼ、およびアミノ酸の生産方法 |
JP2004283167A (ja) * | 2003-03-03 | 2004-10-14 | Ajinomoto Co Inc | 発酵法によるl−アルギニン又はl−リジンの製造法 |
Non-Patent Citations (4)
Title |
---|
BUENO R. ET AL: "Role of glnB and glnD gene products in regulation of the glnALG operon of Escherichia coli.", J BACTERIOL., vol. 164, no. 2, November 1985 (1985-11-01), pages 816 - 822, XP002991722 * |
J.H. MILLER: "Experiments in Molecular Genetics", 1972, COLD SPRING HARBOR LAB. |
JAKOBY M. ET AL: "Nitrogen regulation in Corynebacterium glutamicum: isolation of genes involved and biochemical characterization of corresponding proteins.", FEMS MICROBIOL LETT., vol. 173, no. 2, 15 April 1999 (1999-04-15), pages 303 - 310, XP002226626 * |
MERRICK M.J. ET AL: "Nitrogen control in bacteria.", MICROBIOL REV., vol. 59, no. 4, December 1995 (1995-12-01), pages 604 - 622, XP002991723 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012108493A1 (ja) | 2011-02-09 | 2012-08-16 | 協和発酵バイオ株式会社 | 発酵法による目的物質の製造法 |
WO2013154182A1 (ja) | 2012-04-13 | 2013-10-17 | 協和発酵バイオ株式会社 | アミノ酸の製造法 |
JP7415041B2 (ja) | 2020-03-30 | 2024-01-16 | デサン・コーポレイション | グルタミン生産能を向上させる形質転換用組換えベクターおよびこれを導入した菌株 |
Also Published As
Publication number | Publication date |
---|---|
EP1783203B1 (en) | 2010-01-20 |
ATE455845T1 (de) | 2010-02-15 |
EP1783203A4 (en) | 2007-08-15 |
US20080038786A1 (en) | 2008-02-14 |
CN101065477A (zh) | 2007-10-31 |
ES2337379T3 (es) | 2010-04-23 |
JPWO2006001380A1 (ja) | 2008-04-17 |
EP1783203A1 (en) | 2007-05-09 |
US8211688B2 (en) | 2012-07-03 |
DE602005019063D1 (de) | 2010-03-11 |
CN101065477B (zh) | 2011-10-05 |
JP4898441B2 (ja) | 2012-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5287904B2 (ja) | 目的物質の製造法 | |
JP2020505004A (ja) | 新規ポリペプチド及びこれを用いたimpの生産方法 | |
EP1611241A2 (en) | Method for producing l-amino acid using bacteria having enhanced expression of the gene pcka | |
JP4626220B2 (ja) | 腸内細菌科の細菌を用いたl−ヒスチジンの製造法 | |
JP2003164297A (ja) | 新規変異型グルタミンシンテターゼ、およびアミノ酸の生産方法 | |
JP2020505914A (ja) | 新規ポリペプチド及びこれを用いたimpの生産方法 | |
CN108463555A (zh) | 生产苯甲醛的方法 | |
WO2006001380A1 (ja) | 物質の製造法 | |
BR102018068936A2 (pt) | Método para a produção fermentativa de l-aminoácidos | |
KR101611036B1 (ko) | 대장균에서 대사공학적 방법을 이용한 데옥시사이티딘 생산 균주 개발 | |
KR101830001B1 (ko) | Prpp 합성 경로 개선을 통한 l-트립토판이 과발현되는 균주 및 이를 이용하는 l-트립토판의 제조 방법 | |
KR101530817B1 (ko) | L-트립토판 생산능을 갖는 미생물 및 이를 이용하여 l-트립토판을 생산하는 방법 | |
JP2005073696A (ja) | 不活化したnirオペロンを有する腸内細菌科の細菌を用いたL−アミノ酸の製造法 | |
WO2006025477A1 (ja) | 工業的に有用な微生物 | |
JP6806895B2 (ja) | L−アルギニンを生産するコリネバクテリウム属微生物及びこれを用いたl−アルギニン生産方法 | |
US20210070800A1 (en) | Method of producing a tripeptide gamma-glu-val-gly using enterobacteriaceae | |
JP5064396B2 (ja) | L‐グルタミンの製造法 | |
JP5698001B2 (ja) | アミノ酸の製造法 | |
CN112322601B (zh) | 磷酸烯醇丙酮酸合成酶的突变体及其在产色氨酸方面的应用 | |
JP2002051790A (ja) | コリネ型細菌のアルギニンリプレッサー欠失株及びl−アルギニンの製造法 | |
WO2007037300A1 (ja) | 有用物質の製造法 | |
JP4742521B2 (ja) | 目的物質の製造法 | |
EP3015547B1 (en) | Rna polymerase sigma factor 32 variant and production method for l-threonine using a microorganism expressing the variant | |
CN116121160A (zh) | 过表达pyrB基因的基因工程菌及其生产L-精氨酸的方法 | |
JPWO2008126785A1 (ja) | 有用物質の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200580020513.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11630396 Country of ref document: US Ref document number: 2006528631 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005765117 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005765117 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11630396 Country of ref document: US |